Clinical trial
A Phase 2a Study to Evaluate the Safety and Tolerability of Two Repeated Doses of GM-2505 at a 2-Week Interval in Patients With Major Depressive Disorder.
NCT06236880 is registered in ClinicalTrials.gov with Gilgamesh Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Study to Evaluate the Safety and Tolerability of Two Repeated Doses of GM-2505 at a 2-Week Interval in Patients With Major Depressive Disorder.
- Lead sponsor
- Gilgamesh Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2024
- Completion date
- July 27, 2026
- Enrollment
- 126 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.